NextGen Healthcare has entered a collaboration with Circuit Clinical to enhance trial access to patients of Federally Qualified Health Centers (FQHCs) through more than 14,000 providers that leverage the former’s solutions. 

Traditionally, these underprivileged populations had limited access to take part in transformative clinical research that can offer improved therapy options.

Such research-as-care can boost health outcomes while also generating revenues for the participating clinics. 

The latest partnership between the companies will facilitate in bolstering diverse subject participation in clinical trials and offers enhanced health equity by offering access to such populations.

Furthermore, the alliance adds to the mission of the NextGen Community Health Collaborative, a project announced late last year to provide comparative analytics, data benchmarking and reporting services. 

The initiative also offers a setting for members to network and exchange best practices to progress community health and health equity mission among underserved people.

Subject recruitment to trials, referral and enrolment services will be available through NextGen-steered practices in collaboration with Circuit Clinical, removing barriers to such care. 

In addition, trial participation will offer real benefits to subjects, such as additional care visits without needing co-pays, therapeutic progress on an improved regimen and stipends for patients.

Circuit Clinical founder and CEO Dr Irfan Khan said: “Our partnership with NextGen Healthcare will create a comprehensive solution for improving access to clinical trials for diverse communities across the country. 

“Combining NextGen Healthcare’s comprehensive data insights and national reach with Circuit Clinical’s expert ecosystem offers pharmaceutical, biotech and vaccine companies a ground-breaking opportunity for accelerating therapeutic development and improving diversity in clinical trials.”

In April this year, the US Food and Drug Administration issued new draft guidance  to the industry on developing plans for enrolling more participants from underrepresented racial and ethnic populations in the country into trials.